These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 18206423)

  • 1. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders.
    Abel T; Zukin RS
    Curr Opin Pharmacol; 2008 Feb; 8(1):57-64. PubMed ID: 18206423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders.
    Hahnen E; Hauke J; Tränkle C; Eyüpoglu IY; Wirth B; Blümcke I
    Expert Opin Investig Drugs; 2008 Feb; 17(2):169-84. PubMed ID: 18230051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple roles of HDAC inhibition in neurodegenerative conditions.
    Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
    Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
    Gray SG; Dangond F
    Epigenetics; 2006; 1(2):67-75. PubMed ID: 17998807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creating zinc monkey wrenches in the treatment of epigenetic disorders.
    Kalin JH; Butler KV; Kozikowski AP
    Curr Opin Chem Biol; 2009 Jun; 13(3):263-71. PubMed ID: 19541531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic dysregulation in cognitive disorders.
    Gräff J; Mansuy IM
    Eur J Neurosci; 2009 Jul; 30(1):1-8. PubMed ID: 19508697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human neuronal cells: epigenetic aspects.
    Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
    Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies.
    Urdinguio RG; Sanchez-Mut JV; Esteller M
    Lancet Neurol; 2009 Nov; 8(11):1056-72. PubMed ID: 19833297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.
    Irwin MH; Moos WH; Faller DV; Steliou K; Pinkert CA
    Drug Dev Res; 2016 May; 77(3):109-23. PubMed ID: 26899010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Methylation Regulation in Neurodegenerative Disorders.
    Basavarajappa BS; Subbanna S
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.
    Huber K; Superti-Furga G
    Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic drugs in Alzheimer's disease.
    Cuadrado-Tejedor M; Oyarzabal J; Lucas MP; Franco R; García-Osta A
    Biomol Concepts; 2013 Oct; 4(5):433-45. PubMed ID: 25436752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related epigenetic regulation in the brain and its role in neuronal diseases.
    Kim-Ha J; Kim YJ
    BMB Rep; 2016 Dec; 49(12):671-680. PubMed ID: 27866512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
    Kazantsev AG; Thompson LM
    Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
    Wang F; Fischhaber PL; Guo C; Tang TS
    Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders.
    Rouaux C; Loeffler JP; Boutillier AL
    Biochem Pharmacol; 2004 Sep; 68(6):1157-64. PubMed ID: 15313413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.